T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.47B |
| 2 |
NXP Semiconductors
NXPI
|
+$1.73B |
| 3 |
Tesla
TSLA
|
+$1.7B |
| 4 |
Northrop Grumman
NOC
|
+$1.67B |
| 5 |
Dollar Tree
DLTR
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.29B |
| 2 |
Meta Platforms (Facebook)
META
|
+$1.85B |
| 3 |
Texas Instruments
TXN
|
+$1.82B |
| 4 |
Microsoft
MSFT
|
+$1.27B |
| 5 |
Booking.com
BKNG
|
+$1.18B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.76% |
| 2 | Technology | 16.79% |
| 3 | Consumer Discretionary | 15.26% |
| 4 | Financials | 14.49% |
| 5 | Industrials | 9.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Synaptics
SYNA
$4.2B
| $9.6M | ﹤0.01% |
210,325
-4,400
| -2% | -$209K |
|
|
ITCI
1377
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.57M | ﹤0.01% |
441,178
-400,010
| -48% | -$8.36M |
|
1378
Goodyear
GT
$1.78B
| $9.54M | ﹤0.01% |
408,094
-4,100
| -1% | -$96.4K |
|
1379
Zscaler
ZS
$30.4B
| $9.54M | ﹤0.01% |
+233,876
| New | +$9.45M |
|
1380
Quanta Services
PWR
$101B
| $9.44M | ﹤0.01% |
282,780
| – | – |
|
|
AMAG
1381
DELISTED
AMAG Pharmaceuticals
AMAG
| $9.36M | ﹤0.01% |
468,182
+4,521
| +1% | +$103K |
|
1382
Markel Group
MKL
$22.8B
| $9.32M | ﹤0.01% |
7,841
+34
| +0.4% | +$40K |
|
1383
Sonos
SONO
$1.96B
| $9.28M | ﹤0.01% |
+578,586
| New | +$10.2M |
|
1384
Ternium
TX
$10.7B
| $9.24M | ﹤0.01% |
305,148
+54,092
| +22% | +$1.71M |
|
1385
Warner Bros
WBD
$69.6B
| $9.11M | ﹤0.01% |
284,740
+14,600
| +5% | +$411K |
|
1386
BHP
BHP
$222B
| $9.06M | ﹤0.01% |
203,839
+7,763
| +4% | +$336K |
|
1387
Saia
SAIA
$10.1B
| $9.04M | ﹤0.01% |
118,215
-6,119
| -5% | -$476K |
|
|
WBT
1388
DELISTED
Welbilt, Inc.
WBT
| $9.03M | ﹤0.01% |
432,318
-2,381,495
| -85% | -$52.5M |
|
1389
CRISPR Therapeutics
CRSP
$5.22B
| $8.99M | ﹤0.01% |
202,636
+3,061
| +2% | +$160K |
|
1390
ePlus
PLUS
$2.31B
| $8.96M | ﹤0.01% |
193,256
+186,700
| +2,848% | +$9.32M |
|
1391
Trupanion
TRUP
$1.36B
| $8.84M | ﹤0.01% |
247,280
+44,432
| +22% | +$1.71M |
|
1392
STRATTEC Security
STRT
$338M
| $8.71M | ﹤0.01% |
244,314
-1,400
| -0.6% | -$46.5K |
|
1393
Forte Biosciences
FBRX
$1.57B
| $8.65M | ﹤0.01% |
1,480
+633
| +75% | +$2.41M |
|
|
ESV
1394
DELISTED
Ensco Rowan plc
ESV
| $8.55M | ﹤0.01% |
253,221
+6,172
| +2% | +$177K |
|
1395
Toll Brothers
TOL
$14B
| $8.45M | ﹤0.01% |
255,851
-126,830
| -33% | -$4.59M |
|
1396
Floor & Decor
FND
$6.27B
| $8.41M | ﹤0.01% |
278,924
+11,719
| +4% | +$478K |
|
1397
TripAdvisor
TRIP
$1.29B
| $8.36M | ﹤0.01% |
163,605
-3,800
| -2% | -$208K |
|
1398
uniQure
QURE
$3.26B
| $8.32M | ﹤0.01% |
+228,746
| New | +$8.51M |
|
1399
Assembly Biosciences
ASMB
$594M
| $8.26M | ﹤0.01% |
18,525
+1,034
| +6% | +$484K |
|
1400
White Mountains Insurance
WTM
$5.11B
| $8.04M | ﹤0.01% |
8,595
-366
| -4% | -$339K |
|
Similar funds
T. Rowe Price Associates's Q3 2018 Portfolio in Review
As of Q3 2018, T. Rowe Price Associates held 2,658 positions worth $685B, up 4.7% from $654B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q3 2018 filing shows 77 new, 1,268 increased, 1,098 reduced and 77 closed positions. Its largest new stake was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M. The largest sale was Broadcom, an estimated $3.29B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2018 buy was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M.
- T. Rowe Price Associates added most to NVIDIA in Q3 2018, an estimated $2.47B increase.
- T. Rowe Price Associates's biggest Q3 2018 reduction was Broadcom, cutting an estimated $3.29B.
- T. Rowe Price Associates fully exited DCT Industrial Trust Inc. in Q3 2018, selling an estimated $345M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $685B portfolio in Q3 2018.
- T. Rowe Price Associates opened 77 new positions and closed 77 in Q3 2018.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $685B.
Based on T. Rowe Price Associates's 13F filing for Q3 2018, filed 14 Nov 2018.